Rheumatoid Arthritis and Cholesterol: The Inflammation-Heart Disease Link

Why RA Patients Have Higher Cardiovascular Risk

Chronic systemic inflammation accelerates atherosclerosis. RA is now considered an independent risk factor for coronary artery disease—comparable to diabetes in its impact.

The Lipid Paradox in Active RA

• Active inflammation lowers total cholesterol, LDL, and HDL (the "lipid paradox").
• Effective DMARD therapy often raises lipid levels as inflammation subsides—but the atherogenic risk still drops because lipoprotein quality improves (less oxidation, more functional HDL).

Screening Recommendations (EULAR/ACC)

• Lipid profile at diagnosis, then annually (more often if high risk).
• Measure non-HDL-C or apoB for better risk prediction in inflammatory states.
• Calculate ASCVD risk score; consider coronary calcium scoring if intermediate risk.

Management Strategies

Lifestyle (Foundation)

• Mediterranean diet: increase olive oil, nuts, fish, produce; decrease red meat and refined carbs.
• Exercise: 150 min/week moderate aerobic plus resistance training 2×/week.
• Weight loss if BMI ≥25; even 5% loss improves lipids and inflammation.
• Smoking cessation: the #1 modifiable CV risk factor in RA.
• Stress reduction and adequate sleep.

Pharmacologic

• Statins: First-line for primary and secondary prevention. High-intensity (atorvastatin 40–80 mg, rosuvastatin 20–40 mg) if ASCVD risk ≥7.5% or established CVD.
• Ezetimibe / PCSK9 inhibitors: Add if LDL goal not met or statin intolerant.
• Control RA inflammation: Treat-to-target with DMARDs/biologics—this is the best "lipid-modifying" therapy.
• Review glucocorticoid use: Minimize dose and duration; they raise lipids and glucose.

Monitoring

• Lipids 4–12 weeks after statin initiation or dose change.
• LFTs, CK if symptomatic.
• Annual CV risk reassessment.

Takeaway

Aggressive inflammation control + statin therapy + heart-healthy lifestyle = greatest cardiovascular risk reduction in RA.